Angiomax Generics Imminent After Court Rules Patents Are Invalid
This article was originally published in The Pink Sheet Daily
Executive Summary
Exactly when The Medicine Co.'s top seller will see competition isn't clear – highlighting industry concerns with FDA review times for ANDAs. Hospira and Sagent have tentative approval and several other firms have pending applications.
You may also be interested in...
It Has Been A Long Farewell To The Medicines Company
The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.
Supreme Court And Patents: What’s Not Happening
High court denies petition by Mylan to limit patent litigation venue and petition by Merck KGAA to address whether “on sale” bar to obtaining patent applies to non-public sales; Zarxio case to go to conference Friday.
Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015
District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.